Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
Post-transplant lymphoproliferative disorder (PTLD) is often associated with Epstein-Barr virus (EBV). However, in this report, we describe a heart transplant recipient with pathologically proven EBV-positive PTLD with undetectable virus by polymerase chain reaction. The patient had remission after anti-CD20 antibody treatment early after transplantation.
Garceau
Patrick
P
Institut de Cardiologie de Québec, Hôpital Laval, Sainte-Foy, Québec, Canada.
Couture
Christian
C
Cantin
Bernard
B
Bernier
Vincent
V
Sénéchal
Mario
M
D000293:Adolescent; D000906:Antibodies / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis* / Q000188:drug therapy*; D016027:Heart Transplantation; D004854:Herpesvirus 4, Human; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000188:drug therapy* / Q000821:virology; D008297:Male; D016133:Polymerase Chain Reaction; D000069283:Rituximab; D016896:Treatment Outcome; D019562:Viral Load
D000906:Antibodies; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab